Novel Antibacterial Compounds Formula I Overcoming Bacterial Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibiotic drugs are facing increasing resistance from bacteria, leading to a pressing need for novel antibacterial compounds that can effectively treat infections caused by pathogens like Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli, Acinetobacter baumannii, and Staphylococcus aureus, particularly Gram-negative bacteria.
Innovation Solution
Development of novel compounds of formula (I) with specific structural features, including various functional groups and heterocyclic moieties, which exhibit broad-spectrum antibacterial activity, potentially overcoming resistance issues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current antibiotic drugs are used to treat bacterial infections, then treatment effectiveness is initially good, but bacterial resistance develops leading to treatment failure
Solution Approach 1:
The patent applies parameter changes by developing new chemical compounds with modified molecular structures (formula I with specific substituents R1-R9, A1-A6, B1-B4) that differ from existing antibiotics. This structural parameter change enables the compounds to interact with bacterial targets in novel ways, overcoming resistance mechanisms that have evolved against conventional antibiotics while maintaining treatment effectiveness
Solution Approach 2:
The invention employs composite material principles by creating molecules with multiple functional groups and heterocyclic moieties combined in specific configurations. These composite molecular structures possess both antibacterial activity and resistance-breaking properties, allowing them to effectively treat infections caused by resistant strains of Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli, Acinetobacter baumannii, and Staphylococcus aureus
2Reliability
If novel antibacterial compounds are developed to overcome resistance, then treatment effectiveness against resistant bacteria improves, but development complexity and time increase
Solution Approach 1:
The patent applies segmentation by dividing the molecular structure into distinct functional modules: a core heterocyclic framework (A1-A6), substitutable positions (R1-R9 with specific constraints), and side chain components (B1-B4). This modular segmentation allows systematic optimization of each component's contribution to antibacterial activity and resistance overcoming, reducing overall development complexity through structured design
Solution Approach 2:
The invention implements universality by designing a versatile molecular scaffold (formula I) that can effectively target multiple Gram-negative and Gram-positive bacterial species simultaneously. The compound class demonstrates broad-spectrum activity against Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli, Acinetobacter baumannii, and Staphylococcus aureus, reducing the need for multiple specialized drugs and simplifying treatment protocols
3Adaptability or versatility
If broad-spectrum antibacterial activity is achieved, then treatment versatility improves, but risk of selecting for multiple resistance mechanisms increases
Solution Approach 1:
The patent applies the intermediary principle by designing compounds that target essential bacterial cellular processes (such as cell wall synthesis, protein synthesis, or DNA replication) through novel mechanisms of action. These intermediary targets are critical for bacterial survival but differ from human cellular processes, allowing broad-spectrum activity against diverse bacteria while minimizing the selection pressure for cross-resistance and reducing harmful effects on host organisms
Data Source
AI summary
The invention provides novel compounds having the general formula (I)wherein R1, R2, R3a, R3b, R4, A1, A2, A3, A4, A5, A6, B1, B2, B3, B4, and L are as described herein, compositions including the compounds and methods of using the compounds.